ClinicalTrials.gg
CompletedNCT00055419Updated Apr 9, 2010

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

A Phase 2 interventional study of Cetuximab in Colorectal Neoplasms, sponsored by Eli Lilly and Company. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
744
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
11th of 185
744 · median 60
Started
2003
with 5 others
Phase 2
107 of 187
20 open now
Registered
5th of 187
by date
Lead sponsor
7 of 187
Eli Lilly and Company

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 11th largest by enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2003, is one of 107 in phase 2, and was the 5th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Stage IV colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have signed an approved prior to any study procedures.
  • Subjects with or pathologically confirmed colorectal cancer, which is EGFR-positive by IHC (may be based on )
  • Subjects with performance status 0, 1 or 2.
  • Subjects who have failed, either due to lack of efficacy or due to intolerance, all available chemotherapy for the treatment of metastatic colorectal cancer.
  • Subjects who have failed to meet eligibility criteria for any other existing cetuximab trial.
  • Subjects must have received at least two chemotherapy regimens for metastatic disease OR therapy plus one chemotherapy regimen for metastatic disease, provided the subject progressed within 6 months of completing their adjuvant therapy.
  • Prior chemotherapy must have included all of the follow drugs: irinotecan, oxaliplatin, and a fluoropyrimidine.
  • Subjects adequately recovered from any recent surgery, radiation therapy or chemotherapy.
  • Subjects accessible for treatment and follow-up. Subjects enrolled in this trial must be treated at the participating center.
  • Subjects greater or equal to 18 years of age.
  • Women of must be using an adequate method of to avoid pregnancy throughout the study and for up to 4 weeks afterwards.

Exclusion criteria

Exclusion Criteria:

  • Women of who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study.
  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to study drug administration.
  • Sexually active, fertile men not using adequate .
  • Subjects with dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of .
  • Subjects with a serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.
  • Subjects with a history of uncontrolled angina, arrhythmias, congestive heart failure, or myocardial infarction within the previous 6 months.
  • Subjects with any concurrent other than non-melanoma skin cancer, or carcinoma in situ of the cervix. Subjects with a previous malignancy but without evidence of disease for > 5 years will be allowed to enter the trial.
  • Subjects with any history of severe reactions and/or anaphylaxis resulting from the administration of protein based therapeutic agents.
  • Subjects with inadequate hematologic function defined by an (ANC) \<1,250/mm3, a count \<75,000/mm3, and a level \<8 g/dL.
  • Subjects with inadequate hepatic function, defined by a total level ³3 times the (ULN) and an (AST) and alanine transaminase (ALT) levels >5 x ULN.
  • Subjects with inadequate renal function defined by a serum creatinine level >2.5 x ULN.
  • Prior cetuximab therapy, prior randomization on a study which includes cetuximab therapy in a treatment arm, or any other prior therapy that targets the EGFR pathway.
  • A history of prior therapy with a chimerized or murine monoclonal antibody.
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
  • A history of cetuximab or therapy that targeted the EGFR receptor.
  • A history of prior anti-cancer murine monoclonal antibody therapy.
  • Additional concurrent chemotherapy or other anticancer agents may not be administered to subjects on this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
744 participants (actual)

Study arms

  • Experimental
    400 mg/m2

    Biological: Cetuximab

Interventions

  • BiologicalCetuximab

    400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.

    Time frame: Every 4 weeks untill disease progression

07

Study locations

29 sites
  • ImClone Investigational Site
    Bakersfield, California 93309, United States
  • ImClone Investigational Site
    Los Angeles, California 90025, United States
  • ImClone Investigational Site
    Denver, Colorado 80218, United States
  • ImClone Investigational Site
    Torrington, Connecticut 06790, United States
  • ImClone Investigational Site
    Washington, District of Columbia 20057, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32207, United States
  • ImClone Investigational Site
    Miami, Florida 33176, United States
  • ImClone Investigational Site
    Orlando, Florida 32804, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30318, United States
  • ImClone Investigational Site
    Decatur, Illinois 62526, United States
  • ImClone Investigational Site
    Louisville, Kentucky 40202, United States
  • ImClone Investigational Site
    New Orleans, Louisiana 70121, United States
  • ImClone Investigational Site
    Baltimore, Maryland 21204, United States
  • ImClone Investigational Site
    Ypsilanti, Michigan 48198, United States
  • ImClone Investigational Site
    Minneapolis, Minnesota 55416, United States
  • ImClone Investigational Site
    St Charles, Missouri 63301, United States
  • ImClone Investigational Site
    Great Falls, Montana 59405, United States
  • ImClone Investigational Site
    Las Vegas, Nevada 89109, United States
  • ImClone Investigational Site
    Voorhees, New Jersey 08043, United States
  • ImClone Investigational Site
    East Setauket, New York 11733, United States
  • ImClone Investigational Site
    Latham, New York 12110, United States
  • ImClone Investigational Site
    New York City, New York 10016, United States
  • ImClone Investigational Site
    Cleveland, Ohio 44134, United States
  • ImClone Investigational Site
    Portland, Oregon 97239, United States
  • ImClone Investigational Site
    Greenville, South Carolina 29605, United States
  • ImClone Investigational Site
    Memphis, Tennessee 38104, United States
  • ImClone Investigational Site
    Dallas, Texas 75230, United States
  • ImClone Investigational Site
    Norfolk, Virginia 23502, United States
  • ImClone Investigational Site
    Green Bay, Wisconsin 54307, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Jul 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2003
First posted
Mar 4, 2003
Start
Feb 2003
Primary completionActual
Jul 2004
CompletionActual
Aug 2004
Last update
Apr 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00055419
First posted
Mar 4, 2003
Start date
Feb 2003
Primary completion
Jul 2004
Completion
Aug 2004
Last update
Apr 9, 2010

Study contacts

E-mail: ClinicalTrials@ ImClone.com
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion